Cost analyses of community-acquired pneumonia from the hospital perspective

被引:59
作者
Bauer, TT
Welte, T
Ernen, C
Schlosser, BM
Thate-Waschke, I
de Zeeuw, J
Schultze-Werninghaus, G
机构
[1] Univ Hosp Bergmannsheil, Dept Internal Med 3, Bochum, Germany
[2] Univ Hannover, Dept Pneumol, D-30167 Hannover, Germany
[3] Inst Empir Hlth Econ, Burscheid, Germany
[4] Bayer Vital GMBH, Leverkusen, Germany
关键词
community-acquired pneumonia; cost; length of hospital stay; moxifloxacin;
D O I
10.1378/chest.128.4.2238
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Study objectives: Community-acquired pneumonia (CAP) is a widespread disease with important implications for health-care systems worldwide. This study investigated direct costs, treatment patterns, and outcomes associated with two patient cohorts hospitalized with CAP. Design: The study design was naturalistic, prospective, and open. Patients: The study enrolled 580 patients. Two hundred sixty-one patients were treated initially with IV moxifloxacin (45%, cohort M); the remaining 319 patients received nonstandardized treatment (cohort S). Setting: Twenty-two hospitals in Germany. Results: Clinical success rates were similar between treatment groups (cohort M, 242 of 256 patients, 95%; cohort S, 286 of 312 patients, 92%; p = 0.208). Mean +/- SD length of hospital stay was 10.8 +/- 5.2 days, with cohort M having a significantly shorter hospital stay (10.0 +/- 4 days) compared to cohort S (11.5 +/- 6 days; p < 0.001). Median of all direct costs was $1,333 (minimum, $127; maximum, $9,488), with direct costs of $1,250 in cohort M (minimum, $372; maximum, $9,488) and $1,409 in cohort S (minimum, $127; maximum, $9,366) per treated episode of CAP (p = 0.066). Conclusions: Major determinants of costs were length of hospital stay and ICU admission, whereas costs for staff and hotel were major contributors to direct costs. Initial antibiotic therapy with moxifloxacin resulted in similar clinical efficacy and direct costs compared to nonstandardized therapy; however, patients treated with moxifloxacin benefited with an earlier hospital discharge.
引用
收藏
页码:2238 / 2246
页数:9
相关论文
共 23 条
[1]   A population-based study of the costs of care for community-acquired pneumonia [J].
Bartolomé, M ;
Almirall, J ;
Morera, J ;
Pera, G ;
Ortún, V ;
Bassa, J ;
Bolíbar, I ;
Balanzó, X ;
Verdaguer, A .
EUROPEAN RESPIRATORY JOURNAL, 2004, 23 (04) :610-616
[2]   A comparison of observational studies and randomized, controlled trials. [J].
Benson, K ;
Hartz, AJ .
NEW ENGLAND JOURNAL OF MEDICINE, 2000, 342 (25) :1878-1886
[3]   Adherence to guidelines for community-acquired pneumonia - Does it decrease cost of care? [J].
Brown, PD .
PHARMACOECONOMICS, 2004, 22 (07) :413-420
[4]   Efficacy and safety of oral and early-switch therapy for community-acquired pneumonia:: A randomized controlled trial [J].
Castro-Guardiola, A ;
Viejo-Rodríguez, AL ;
Soler-Simon, S ;
Armengou-Arxé, A ;
Bisbe-Company, V ;
Peñarroja-Matutano, G ;
Bisbe-Company, J ;
García-Bragado, F .
AMERICAN JOURNAL OF MEDICINE, 2001, 111 (05) :367-374
[5]   Treatment costs of community-acquired pneumonia in an employed population [J].
Colice, GL ;
Morley, MA ;
Asche, C ;
Birnbaum, HG .
CHEST, 2004, 125 (06) :2140-2145
[6]   An economic evaluation of sequential IV/po moxifloxacin therapy compared to IV/po co-amoxidav with or without clarithromycin in the treatment of community-acquired pneumonia [J].
Drummond, MF ;
Becker, DL ;
Hux, M ;
Chancellor, JVM ;
Duprat-Lomon, I ;
Kubin, R ;
Sagnier, PP .
CHEST, 2003, 124 (02) :526-535
[7]  
DRUMMOND MF, 1987, CRITICAL ASSESSMENT, P18
[8]   Randomized controlled trial of sequential intravenous (i.v.) and oral moxifloxacin compared with sequential i.v. and oral co-amoxiclav with or without clarithromycin in patients with community-acquired pneumonia requiring initial parenteral treatment [J].
Finch, R ;
Schürmann, D ;
Collins, O ;
Kubin, R ;
McGivern, J ;
Bobbaers, H ;
Izquierdo, JL ;
Nikolaides, P ;
Ogundare, F ;
Raz, R ;
Zuck, P ;
Hoeffken, G .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2002, 46 (06) :1746-1754
[9]   Relation between length of hospital stay and costs of care for patients with community-acquired pneumonia [J].
Fine, MJ ;
Pratt, HM ;
Obrosky, DS ;
Lave, JR ;
McIntosh, LJ ;
Singer, DE ;
Coley, CM ;
Kapoor, WN .
AMERICAN JOURNAL OF MEDICINE, 2000, 109 (05) :378-385
[10]   A prediction rule to identify low-risk patients with community-acquired pneumonia [J].
Fine, MJ ;
Auble, TE ;
Yealy, DM ;
Hanusa, BH ;
Weissfeld, LA ;
Singer, DE ;
Coley, CM ;
Marrie, TJ ;
Kapoor, WN .
NEW ENGLAND JOURNAL OF MEDICINE, 1997, 336 (04) :243-250